Study of ALZ Adopts BYOD Technology
Datacubed Health’s mobile platform has been selected to support studies for those at risk of Dominantly Inherited Alzheimer’s Disease, a rare form of early-onset Alzheimer’s Disease. The Linkt platform enables the collection of real-time data on sleep, diet and other biomarkers using a “bring your own device” (BYOD) study model.
Datacubed Health’s app, platform and web-based portal will be used by scientists at the Dominantly Inherited Alzheimer Network (DIAN) at the Washington University School of Medicine in Saint Louis. The DIAN research incorporates an observational study, clinical drug trials, a research registry and smaller ancillary studies.
The app and portal utilize a gamified experience with rewards for completion and compliance. Participants navigate an interactive map journey creating variable rewards such as digital gems and visual progress as they complete articles, surveys and tasks. Datacubed Health’s tools allow researchers and study coordinators to enroll participants, monitor real-time progress and compliance dashboards, manage incentives and review study data.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
